Literature DB >> 28756877

Platelet populations and priming in hematological diseases.

Constance C F M J Baaten1, Hugo Ten Cate2, Paola E J van der Meijden3, Johan W M Heemskerk4.   

Abstract

In healthy subjects and patients with hematological diseases, platelet populations can be distinguished with different response spectra in hemostatic and vascular processes. These populations partly overlap, and are less distinct than those of leukocytes. The platelet heterogeneity is linked to structural properties, and is enforced by inequalities in the environment. Contributing factors are variability between megakaryocytes, platelet ageing, and positive or negative priming of platelets during their time in circulation. Within a hemostatic plug or thrombus, platelet heterogeneity is enhanced by unequal exposure to agonists, with populations of contracted platelets in the thrombus core, discoid platelets at the thrombus surface, patches of ballooned and procoagulant platelets forming thrombin, and coated platelets binding fibrin. Several pathophysiological hematological conditions can positively or negatively prime the responsiveness of platelet populations. As a consequence, in vivo and in vitro markers of platelet activation can differ in thrombotic and hematological disorders.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Activation markers; Platelet heterogeneity; Positive priming; Thrombus

Mesh:

Year:  2017        PMID: 28756877     DOI: 10.1016/j.blre.2017.07.004

Source DB:  PubMed          Journal:  Blood Rev        ISSN: 0268-960X            Impact factor:   8.250


  24 in total

1.  Phosphoproteomic quantitation and causal analysis reveal pathways in GPVI/ITAM-mediated platelet activation programs.

Authors:  Özgün Babur; Alexander R Melrose; Jennifer M Cunliffe; John Klimek; Jiaqing Pang; Anna-Liisa I Sepp; Jevgenia Zilberman-Rudenko; Samuel Tassi Yunga; Tony Zheng; Iván Parra-Izquierdo; Jessica Minnier; Owen J T McCarty; Emek Demir; Ashok P Reddy; Phillip A Wilmarth; Larry L David; Joseph E Aslan
Journal:  Blood       Date:  2020-11-12       Impact factor: 22.113

Review 2.  Platelet Abnormalities in CKD and Their Implications for Antiplatelet Therapy.

Authors:  Constance C F M J Baaten; Jonas R Schröer; Jürgen Floege; Nikolaus Marx; Joachim Jankowski; Martin Berger; Heidi Noels
Journal:  Clin J Am Soc Nephrol       Date:  2021-11-08       Impact factor: 8.237

3.  Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis.

Authors:  H M H Spronk; T Padro; J E Siland; J H Prochaska; J Winters; A C van der Wal; J J Posthuma; G Lowe; E d'Alessandro; P Wenzel; D M Coenen; P H Reitsma; W Ruf; R H van Gorp; R R Koenen; T Vajen; N A Alshaikh; A S Wolberg; F L Macrae; N Asquith; J Heemskerk; A Heinzmann; M Moorlag; N Mackman; P van der Meijden; J C M Meijers; M Heestermans; T Renné; S Dólleman; W Chayouâ; R A S Ariëns; C C Baaten; M Nagy; A Kuliopulos; J J Posma; P Harrison; M J Vries; H J G M Crijns; E A M P Dudink; H R Buller; Y M C Henskens; A Själander; S Zwaveling; O Erküner; J W Eikelboom; A Gulpen; F E C M Peeters; J Douxfils; R H Olie; T Baglin; A Leader; U Schotten; B Scaf; H M M van Beusekom; L O Mosnier; L van der Vorm; P Declerck; M Visser; D W J Dippel; V J Strijbis; K Pertiwi; A J Ten Cate-Hoek; H Ten Cate
Journal:  Thromb Haemost       Date:  2018-01-29       Impact factor: 5.249

Review 4.  Platelet Proteomes, Pathways, and Phenotypes as Informants of Vascular Wellness and Disease.

Authors:  Joseph E Aslan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2021-01-14       Impact factor: 8.311

5.  Procoagulant platelets: Generation, characteristics, and therapeutic target.

Authors:  Yaxin Chu; Han Guo; Yuncong Zhang; Rui Qiao
Journal:  J Clin Lab Anal       Date:  2021-03-11       Impact factor: 2.352

6.  Platelet Function in CKD: A Systematic Review and Meta-Analysis.

Authors:  Constance C F M J Baaten; Marieke Sternkopf; Tobias Henning; Nikolaus Marx; Joachim Jankowski; Heidi Noels
Journal:  J Am Soc Nephrol       Date:  2021-05-03       Impact factor: 14.978

Review 7.  Platelet Subtypes in Inflammatory Settings.

Authors:  Muataz Ali Hamad; Krystin Krauel; Nancy Schanze; Nadine Gauchel; Peter Stachon; Thomas Nuehrenberg; Mark Zurek; Daniel Duerschmied
Journal:  Front Cardiovasc Med       Date:  2022-04-07

Review 8.  Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics.

Authors:  Erica Gianazza; Maura Brioschi; Roberta Baetta; Alice Mallia; Cristina Banfi; Elena Tremoli
Journal:  Int J Mol Sci       Date:  2020-06-25       Impact factor: 5.923

9.  Impaired mitochondrial activity explains platelet dysfunction in thrombocytopenic cancer patients undergoing chemotherapy.

Authors:  Constance C F M J Baaten; Floor C J I Moenen; Yvonne M C Henskens; Frauke Swieringa; Rick J H Wetzels; René van Oerle; Harry F G Heijnen; Hugo Ten Cate; Graham P Holloway; Erik A M Beckers; Johan W M Heemskerk; Paola E J van der Meijden
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

10.  Droplet Microfluidics with Reagent Micromixing for Investigating Intrinsic Platelet Functionality.

Authors:  Maaike S A Jongen; Paul M Holloway; Simon I R Lane; Nicola A Englyst; Owen J T McCarty; Jonathan West
Journal:  Cell Mol Bioeng       Date:  2021-01-21       Impact factor: 2.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.